New vaccine combo targets rare liver cancer in early trial
NCT ID NCT04248569
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a peptide vaccine designed to target a specific protein found in fibrolamellar carcinoma (FLC), a rare liver cancer. The vaccine is combined with two immunotherapy drugs (nivolumab and ipilimumab) to boost the immune system's attack on cancer cells. The study enrolls about 56 people with advanced FLC or other tumors carrying the same genetic change. The main goals are to check safety and measure immune response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DNAJB1-PRKACA peptide vaccine (Hiltonol) plus nivolumab and ipilimumab
What this could lead to
If successful, this could point toward a new treatment option for fibrolamellar carcinoma, a rare liver cancer with few effective therapies.
What could go wrong
This is an early phase 1 trial focused on safety, not yet proven to shrink tumors or extend life. The combination of drugs may cause significant side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FIBROLAMELLAR HEPATOCELLULAR CARCINOMA (FLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sidney Kimmel Comprehensive Cancer Center
RECRUITINGBaltimore, Maryland, 21231, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact